Ältere Originalarbeiten

 

Schmitz S, Heymanns J.
Interdisziplinäre ambulante Versorgung
Der Onkologe 2009;15:1065-1069.
Weide R, Mergenthaler U, Friesenhahn V, Kleboth K, Heymanns J, Thomalla J, Köppler H.
Bendamustine/Mitoxantrone/Rituximab (BMR): A short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia (CLL)
Leuk. Lymphoma. 2009;50(9):1468-1474.
Rhiem K, Wappenschmidt B, Bosse K, Köppler H, Tutt AN, Schmutzler RK.
Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.
Clin Oncol (R Coll Radiol). 2009; 21(6):448-50.
Diel IJ, Weide R, Köppler H, Antrás L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Support Care Cancer. 2009; 17(6):719-25.
Steil S, Zerwas S, Moos G, Bittinger F, Hansen T, Mergenthaler U, Weide R.
CT-guided percutaneous core needle biopsy in oncology outpatients:sensitivity, specificity, complications.
Onkologie. 2009; 32(5):254-8.
Weide R, Mergenthaler U, Pandorf A, Arndt H, Heymanns J, Thomalla J, Köppler H.
Improved survival of patients with metastatic breast cancer in routine care: results of retrospective study in a community-based oncology group practice 1995-2005
Onkologie. 2009; 32(3):107-13.
Koeppler H, Heymanns J, Thomalla J, Kleboth K, Mergenthaler U, Weide R.
Treatment of Advanced Non Small Cell Lung Cancer in Routine Care: A Retrospective Analysis of 212 Consecutive Patients Treated in a Community Based Oncology Group Practice. Clinical Medicine: Oncology 2009: 3 63-70.
Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, Fries S, Knoblich J, Köchling G, Laubenstein HP, Petrides P, Planker M, Pihusch R, Weide R, Kern W, Haferlach T.
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis
Haematologica. 2009; 94(1):141-4.
Weide R
Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
Therapeutics and Clinical Risk Management 2008; 4(4):1-6.
Weide R, Arndt M, Pandorf A, Heymanns J, Thomalla J, Köppler H.
Ovarian Cancer Treatment Reality in Northern Rheinland-Pfalz (Germany). Suboptimal Surgical Treatment as the Cause for inferior survival. A Retrospective Study of 139 Consecutive Patients Receiving Chemotherapy and Palliative Care in an Oncology Group Practice.
Onkologie 2007; 30:611-617.
Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M.
High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicenter Phase II Study of the German Low Grade Lymphoma Study Group (GLSG). Leukemia and Lymphoma (2007), 48(7):1299-1306
Weide R, Heymanns J, Thomalla J, Köppler H.
Interaktiver Kleingruppenunterricht für Medizinstudenten der klinischen Semester in einer onkologischen Gemeinschaftspraxis
GMS Z Med Ausbild (2007),24(1):Doc71